For the last three years, GLP-1 medications have looked like the high-water mark of medical weight management. The headline numbers were genuinely impressive. Semaglutide produced around 15% weight loss in trial settings. Tirzepatide pushed that closer to 21%. The conversation in clinics, in podcasts, and in newspapers has settled into a kind of consensus: this is the ceiling, this is what modern medicine can do for obesity, this is the new normal.
The consensus was reasonable. It was also already wrong.
In December 2025, Eli Lilly reported the TRIUMPH-4 results for retatrutide, its next-generation obesity therapy. Patients on the highest dose lost an average of 28.7% of their body weight at 68 weeks. Roughly one in eight patients with knee osteoarthritis became completely free of knee pain by the end of the trial. These are not incremental improvements over what came before. They reset the conversation.
Worth being specific here. Retatrutide is not a tweaked GLP-1. It’s a triple agonist: a single molecule that activates three different hormone receptors at once: GLP-1, GIP, and glucagon. The third one is the interesting move. Glucagon is the hormone that classically raises blood sugar, which is exactly why early researchers would have considered it the wrong target for a metabolic medication. The science has caught up. Activating glucagon receptors increases energy expenditure (your body burns more), which compounds with the appetite-reducing effects of GLP-1 and GIP. The result is the largest weight-reduction effect ever recorded in a Phase 3 obesity trial.
The reason this matters for anyone thinking about weight management is not that retatrutide is the answer. It isn’t yet, and the side effect profile in TRIUMPH-4 included some new signals that need careful watching, particularly dysesthesia (an unusual sensation of touch) in around 21% of patients on the highest dose. The reason it matters is that it changes the right way to think about timing.
Three things worth saying plainly.
The pace of advancement is faster than most people assume
Semaglutide was first approved by the FDA for obesity in 2021. Tirzepatide followed in 2023. Retatrutide is on track for FDA submission in late 2026, with approval likely in 2027–2028. Three meaningfully different generations of medication in seven years, a tempo more familiar from consumer technology than from pharmaceutical development. In the same window, Lilly’s TRIUMPH program has seven more Phase 3 readouts coming in 2026 alone, covering obesity, type 2 diabetes, sleep apnoea, low back pain, fatty liver disease, and cardiovascular outcomes. The next generation of evidence is already in the pipeline.
Australia is on a longer timeline than the United States
Retatrutide is not approved by the TGA, and won’t be soon. The realistic window for TGA approval is somewhere between late 2027 and 2029, depending on whether Eli Lilly seeks accelerated review and how quickly the TRIUMPH-1 and TRIUMPH-2 weight-management trials report. PBS listing, the step that determines whether the medication is subsidised for Australian patients, usually adds another 12 to 24 months on top of TGA approval. So a working assumption for retatrutide as a private prescription in Australia is somewhere in 2028–2029. PBS-listed and affordable: later, possibly meaningfully later.
The question that actually matters for decisions today
If you’re considering medication-assisted weight loss now, the right question is not “should I wait for retatrutide.” The right question is whether the current generation of medications fits your goals, your medical context, and your tolerance for the trade-offs they involve. Semaglutide and tirzepatide remain very effective interventions for many people. They will continue to be the right choice for many people even after retatrutide is approved, because the higher efficacy of newer medications also brings higher rates of side effects, higher costs, and, critically, newer drugs always have less long-term safety data than the ones they replace.
A better mental model than “wait for the ceiling to rise” is this: the medications keep getting better, and the standard of care keeps moving with them. The question to bring to a clinical conversation isn’t “what’s the most powerful drug available.” It’s “what’s the right intervention for me, now, given what we know.”
What this means in practice
If you’re already considering medication-assisted weight management, the news from TRIUMPH-4 is interesting context, not a reason to delay. The medications available today are well-understood, increasingly affordable, and demonstrably effective in carefully managed clinical settings. If you’re at the edge of considering whether the field has matured enough to be worth engaging with, the answer is yes, and the pace suggests it will continue maturing fast.
The harder, less-discussed question, the one we’ll return to in a separate piece, is what happens to all of this when the medication is eventually stopped. Retatrutide does not change the answer to that question, and neither did its predecessors. The arc that holds the result in place is built from things the medication doesn’t supply: protein, resistance training, sleep, and the long arc of habit. Those parts of the conversation matter more, not less, as the medications get more powerful.